Application of PPAR agonist in the preparation of medicine for treating follicular lymphoma
By developing PPAR agonists with levolial isomers, crystalline, amorphous or pharmaceutically acceptable salts, activate PPARα, inhibit the proliferation of follicular lymphoma cells and induce apoptosis, the current solution is to be solved There are treatments that cannot cure follicular lymphoma, providing new therapeutic strategies and drug embedded points.
Patent Information
- Application Number
- CN202310762733.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-26
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-06-26
AI Technical Summary
The existing treatment methods for follicular lymphoma cannot be effectively cured. About 20% of patients will experience refractory or early recurrence within the first two years after chemoimmunotherapy, and siglitaxel or its levotraeliform isomers, The mechanism of application of crystalline, amorphous or pharmaceutically acceptable salts in the treatment of follicular lymphoma is unknown.
PPAR agonists with levocarboxylic or its levoid isomer, crystalline, amorphous or pharmaceutically acceptable salts were developed to inhibit FOXM1 and its downstream target genes C-MYC and CyclinD1 by activating PPARα in FL cells. , expression of CyclinE1 and CyclinB1 prevents cell cycle progression, inhibits the proliferation of follicular lymphoma cells and induces apoptosis, and thus inhibits the tumorigenesis process of follicular lymphoma.
Inhibition of the proliferation of follicular lymphoma cells at the molecular and cellular level and promote their apoptosis. The CDX mouse model verified that siglitazole can inhibit the tumorigenesis process of follicular lymphoma in mice, and is a follicular The treatment of sexual lymphoma provides new theoretical basis and drug embedded points.
Smart Images

Figure CN116602962B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine and relates to the use of a PPAR agonist, in particular cigligliptin or its levorotatory isomer, crystalline form, amorphous form or pharmaceutically acceptable salt in the preparation of a drug for treating follicular lymphoma. Background Art
[0002] Follicular lymphoma (FL) is usually an indolent B-cell lymphoproliferative disease composed of transformed follicular center B cells. Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, and splenomegaly. FL patients generally present with asymptomatic lymphadenopathy, which may fluctuate repeatedly or undergo malignant transformation, and about 70% of patients have bone marrow involvement. (See Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022 Dec; 97(12): 1638-1651.) Relapsed FL patients have a wide range of treatment options, including some chemoimmunotherapy regimens, phosphoinositide 3-kinase inhibitors, and lenalidomide plus rituximab. However, despite improvements in frontline treatment, traditional FL treatment is still incurable, and about 20% of patients will still experience refractory or early relapse within the first 2 years after chemoimmunotherapy. Cell cycle regulation is an important regulatory mechanism for tumor cell proliferation. Cell cycle protein inhibitors can hinder the progression of tumor cell cycle and thus inhibit the proliferation level of tumor cells.
[0003] Chiglitazar is a diabetes treatment drug independently designed and synthesized by Shenzhen Microchip Biotech Co., Ltd. in my country, with a new chemical structure and global intellectual property protection. It has full activation effects on PPARα, PPARδ and PPARγ, and belongs to a new generation of insulin sensitizers. It is mainly used for the treatment of type 2 diabetes (see Cheng HS, Tan WR, Low ZS, Marvalim C, Lee JYH, Tan NS. Exploration and Development of PPARModulators in Health and Disease: An Update of Clinical Evidence. Int J Mol Sci. 2019 Oct 11; 20(20): 5055).
[0004] However, it is still unclear whether cigligliptin or its levorotatory isomer, crystalline form, amorphous form or pharmaceutically acceptable salt can be used to treat follicular lymphoma and its mechanism of action on follicular lymphoma-related cell lines. Summary of the invention
[0005] In view of the deficiencies of the prior art, the object of the present invention is to provide a PPAR agonist, especially cigligliptin or its levorotatory isomer, crystalline form, amorphous form or pharmaceutically acceptable salt for use in the preparation of a drug for treating follicular lymphoma.
[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0007] In a first aspect, the present invention provides the use of a PPAR agonist in the preparation of a drug for treating follicular lymphoma; the PPAR agonist is selected from cigligliptin or any one of its levorotatory isomers, crystalline forms, amorphous forms or pharmaceutically acceptable salts.
[0008] The present invention develops a new drug use of cigligliptin or its L-isomer, crystalline form, amorphous form or pharmaceutically acceptable salt, and proves that it can inhibit the cell cycle of follicular lymphoma cell lines at the molecular level, and can activate the protein expression of PPARα in FL cells. After activation, PPARα binds to the promoter region of transcription factor FOXM1, thereby inhibiting the expression of FOXM1 and its downstream target genes C-MYC, CyclinD1, CyclinE1 and CyclinB1, inhibiting the cell proliferation and cycle progression of FL cells, and finally inhibiting the occurrence and development of FL. The schematic diagram is shown in FIG. Fig.10 As shown. At the same time, it can inhibit the proliferation of follicular lymphoma cell lines and induce their apoptosis level at the cellular level; in animal experiments, it also proved that sitagliptin sodium can inhibit the tumor formation process of mouse follicular lymphoma through the CDX mouse model. The present invention provides a theoretical basis for studying the treatment strategy of follicular lymphoma and provides an insertion point for preparing new drugs for treating follicular lymphoma.
[0009] In the present invention, the PPAR agonist inhibits the proliferation of follicular lymphoma cells.
[0010] In the present invention, the PPAR agonist induces apoptosis of follicular lymphoma cells.
[0011] In the present invention, the PPAR agonist inhibits the clonogenicity of follicular lymphoma cells.
[0012] Preferably, the pharmaceutically acceptable salt is any one of an alkali metal salt, an alkaline earth metal salt, an ammonium salt or a quaternary ammonium salt.
[0013] Preferably, the pharmaceutically acceptable salt is an alkali metal salt.
[0014] Preferably, the pharmaceutically acceptable salt is a sodium salt or a potassium salt.
[0015] In the present invention, the PPAR agonist down-regulates the expression level of transcription factor FOXM1 and its cell cycle-related genes.
[0016] Preferably, the cell cycle-related genes include any one or a combination of at least two of CyclinB1, C-MYC, CyclinD1 or CyclinE1.
[0017] In the present invention, the medicine further contains pharmaceutically acceptable excipients.
[0018] Preferably, the pharmaceutically acceptable excipients include any one or a combination of at least two of carriers, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, antibacterial agents or buffers.
[0019] Preferably, the drug further contains other active ingredients. The other active ingredients may produce a synergistic effect with cigliptin or its levorotatory isomer, crystalline form, amorphous form or pharmaceutically acceptable salt, or the two may produce an additive effect, preferably without producing an antagonistic effect on cigliptin or its levorotatory isomer, crystalline form, amorphous form or pharmaceutically acceptable salt.
[0020] In a second aspect, the present invention also provides the use of a PPAR agonist in the preparation of a follicular lymphoma cell line proliferation inhibitor, a follicular lymphoma cell line apoptosis promoter or a follicular lymphoma cell line cell cycle inhibitor; the PPAR agonist is selected from any one of cigligliptin or its levorotatory isomer, crystalline form, amorphous form or pharmaceutically acceptable salt.
[0021] Preferably, the follicular lymphoma cell line comprises any one of SC-1 cells, Karpas 422 cells or RL cells, or a combination of at least two of them.
[0022] In a third aspect, the present invention also provides the use of a PPAR agonist in the preparation of a reagent having the efficacy of inhibiting proliferation of follicular lymphoma cell lines and promoting apoptosis of follicular lymphoma cell lines.
[0023] According to the research results of the present invention, it is found that cigliglan or its L-isomer, crystalline form, amorphous form or pharmaceutically acceptable salt has the effect of inhibiting the proliferation of follicular lymphoma cell lines and promoting the apoptosis of follicular lymphoma cell lines, because it can also be used as a separate scientific research reagent for basic scientific research, for example, for exploring the relevant mechanisms of follicular lymphoma cells.
[0024] Compared with the prior art, the present invention has the following beneficial effects:
[0025] The present invention develops a new drug use of cigligliptin or its L-isomer, crystalline form, amorphous form or pharmaceutically acceptable salt, and proves that it can inhibit the cell cycle of follicular lymphoma cell lines at the molecular level, downregulate the expression level of transcription factor FOXM1 and its cell cycle-related genes CyclinB1, C-MYC, CyclinD1 or CyclinE1, thereby inhibiting the progression of follicular lymphoma. The schematic diagram is shown as follows Fig.10 As shown in the figure, it can inhibit the proliferation of follicular lymphoma cell lines and induce apoptosis at the cellular level; in animal experiments, it also proved that sitagliptin can inhibit the tumor formation process of follicular lymphoma in mice through CDX mouse model. The present invention provides a theoretical basis for studying the treatment strategy of follicular lymphoma and provides an insertion point for preparing new drugs for treating follicular lymphoma. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1A This is the result graph of cell proliferation inhibition rate after SC-1 cells were treated with sitagliptin for 24h and 48h;
[0027] Figure 1B The figure shows the cell proliferation inhibition rate of Karpas 422 cells after treatment with sitagliptin for 24h and 48h;
[0028] Figure 1C This is the result graph of cell proliferation inhibition rate of RL cells after treatment with sitagliptin for 24h and 48h;
[0029] Figure 2A The figure shows the flow cytometry results of cell apoptosis in SC-1 cells after treatment with sitagliptin for 24h and 48h;
[0030] Figure 2B This is the statistical result of apoptosis rate of SC-1 cells after treatment with sitagliptin for 24h and 48h;
[0031] Figure 2C The figure shows the flow cytometry results of apoptosis level in Karpas 422 cells after treatment with sitagliptin for 24h and 48h;
[0032] Figure 2D This is a statistical graph of the apoptosis rate of Karpas 422 cells after treatment with sitagliptin for 24h and 48h;
[0033] Figure 2E The figure shows the flow cytometry results of apoptosis level in RL cells after treatment with sitagliptin for 24h and 48h;
[0034] Figure 2F This is the statistical result of apoptosis rate of RL cells after treatment with Siglitstat for 24h and 48h;
[0035] Figure 3A This is a statistical result diagram of the percentage of cells in the G1 phase, S phase and G2 phase of the cell cycle after SC-1 cells were treated with sitagliptin;
[0036] Figure 3B This is a statistical result graph of the percentage of cells in the G1 phase, S phase and G2 phase of the cell cycle after Karpas 422 cells were treated with Siglitstat;
[0037] Figure 3C This is a statistical result diagram of the percentage of cells in the G1 phase, S phase and G2 phase of the cell cycle after RL cells were treated with sitagliptin;
[0038] Figure 4A The colony formation diagram of SC-1 cells treated with different concentrations of sitagliptin;
[0039] Figure 4B This is a statistical graph of the clone formation of SC-1 cells treated with different concentrations of sitagliptin;
[0040] Figure 4C The figure shows the colony formation of Karpas 422 cells treated with different concentrations of Siglistatin;
[0041] Figure 4D The figure shows the statistical results of clone formation of Karpas 422 cells treated with different concentrations of Siglitstat;
[0042] Figure 4E The colony formation diagram of RL cells treated with different concentrations of sitagliptin;
[0043] Figure 4F This is a statistical graph of the clone formation of RL cells treated with different concentrations of Siglitstat;
[0044] Figure 5A The Western blot results of SC-1 cells treated with different concentrations of Siglitstat for 24 hours;
[0045] Figure 5B The Western blot results of Karpas 422 cells treated with different concentrations of Siglitstat for 24 hours;
[0046] Figure 5C The Western blot results of RL cells treated with different concentrations of Siglitstat for 24 hours;
[0047] Fig. 6AThe Western blot results of the expression levels of transcription factor FOXM1 and its downstream target genes C-MYC, CyclinD1, CyclinE1 and CyclinB1 in SC-1 cells treated with different concentrations of Siglitstat for 24 hours;
[0048] Figure 6B The Western blot results of the expression levels of transcription factor FOXM1 and its downstream target genes C-MYC, CyclinD1, CyclinE1 and CyclinB1 in Karpas 422 cells treated with different concentrations of Siglitstat for 24 hours;
[0049] Figure 6C The Western blot results of the expression levels of transcription factor FOXM1 and its downstream target genes C-MYC, CyclinD1, CyclinE1 and CyclinB1 in RL cells treated with different concentrations of Siglitstat for 24 hours;
[0050] Fig. 7A The figure shows the mRNA level statistics of transcription factor FOXM1 and its downstream target genes C-MYC, CyclinD1, CyclinE1 and CyclinB1 after SC-1 cells were treated with different concentrations of Siglitstat for 24 hours;
[0051] Figure 7B The mRNA level statistics of transcription factor FOXM1 and its downstream target genes C-MYC, CyclinD1, CyclinE1 and CyclinB1 in Karpas 422 cells treated with different concentrations of Siglitstat for 24 hours;
[0052] Figure 7C The figure shows the mRNA level statistics of transcription factor FOXM1 and its downstream target genes C-MYC, CyclinD1, CyclinE1 and CyclinB1 after RL cells were treated with different concentrations of Siglitstat for 24 hours;
[0053] Fig. 8A This is the result diagram of the enrichment of activated PPARα in the promoter region of transcription factor FOXM1 after SC-1 cells were treated with sitagliptin for 48 hours;
[0054] Figure 8B This is the result diagram showing that activated PPARα is enriched in the promoter region of transcription factor FOXM1 after RL cells were treated with sitagliptin for 48 hours;
[0055] Figure 8C The figure shows the expression result of PPARα transcriptional inhibition of FOXM1 24 hours after 293T cells were transfected;
[0056] Fig.9A This is a picture of the tumor sample taken on the 10th day after the injection of sitagliptin into the SC-1 cell subcutaneous transplanted CDX mouse model;
[0057] Fig. 9B The figure shows the tumor volume statistics on day 0, day 5 and day 10 after injecting sitagliptin into the SC-1 cell subcutaneous transplanted tumor CDX mouse model;
[0058] Fig. 9C This is a statistical graph of tumor weight on the 10th day after the injection of sitagliptin into the SC-1 cell subcutaneous transplanted tumor CDX mouse model;
[0059] Fig.9D This is a picture of the tumor sample taken on the 10th day after the injection of sitagliptin into the RL cell subcutaneous transplanted tumor CDX mouse model;
[0060] Fig.9E The figures are the statistical graphs of tumor volumes on days 0, 5, and 10 after injection of sitagliptin into the RL cell subcutaneous transplanted tumor CDX mouse model;
[0061] Fig.9F The statistical graph of tumor weight on the 10th day after the injection of sitagliptin into the RL cell subcutaneous transplanted tumor CDX mouse model;
[0062] Fig.10 Schematic diagram of the mechanism of action of sitagliptin in the present invention in inhibiting the occurrence and development of FL. DETAILED DESCRIPTION
[0063] The technical solution of the present invention is further described below in conjunction with the accompanying drawings and through specific implementation methods. However, the following examples are only simple examples of the present invention and do not represent or limit the scope of protection of the present invention. The scope of protection of the present invention shall be subject to the claims.
[0064] In the following examples, unless otherwise specified, all reagents and consumables used were purchased from conventional reagent manufacturers in the field; unless otherwise specified, all experimental methods and technical means used were conventional methods and means in the field.
[0065] The drug sitagliptin sodium involved in the following examples was provided by Shenzhen Chipscreen Biotech Co., Ltd.
[0066] Example 1 Siglitstat inhibits proliferation of follicular lymphoma (FL) cell lines
[0067] Take 1×10 4 Logarithmic growth phase FL cell lines SC-1, Karpas 422 and RL cells were inoculated in 96-well cell culture plates, respectively. SC-1, Karpas 422 and RL cell lines were provided by the Institute of Hematology, Medical College, Xiamen University;
[0068] The cells were treated with DMSO in the control group, and the concentration gradient of sitagliptin sodium in the experimental group was set at 5 μM, 10 μM, 20 μM, 30 μM, and 40 μM;
[0069] The cell proliferation level was detected using the CCK8 kit after treatment for 24 h and 48 h.
[0070] The cell proliferation results were as follows Figure 1A , Figure 1B , Figure 1C As shown;
[0071] After treating SC-1, Karpas 422 and RL cells with Siglitstat for 24h and 48h respectively, the IC50 values of Siglitstat detected are shown in Table 1 below:
[0072] Table 1
[0073]
[0074] Combined with the above results, it can be seen that sitagliptin sodium can inhibit the proliferation level of FL cells and show time and concentration dependence; with the increase of treatment concentration and treatment time, its inhibition rate gradually increases.
[0075] Example 2 Siglitstat induces apoptosis in follicular lymphoma (FL) cell lines
[0076] Take 1×10 5 Logarithmic growth phase FL cell lines SC-1, Karpas 422, and RL were seeded in 24-well cell culture plates;
[0077] The cells were treated with DMSO in the control group, and the concentration gradient of sitagliptin sodium in the experimental group was set at 2.5 μM, 5 μM, 10 μM, 20 μM, and 40 μM;
[0078] After 24h and 48h of treatment, the cell apoptosis level was detected by Annexin V / PI flow cytometry and the cell apoptosis rate was calculated.
[0079] Figure 2A and Figure 2B The results of flow cytometry and apoptosis rate of SC-1 cells treated with different concentrations of Siglitstat after 24h and 48h.
[0080] Figure 2C and Figure 2D The results of flow cytometry and apoptosis rate of Karpas 422 cells treated with different concentrations of Siglitstat at 24h and 48h.
[0081] Figure 2E and Figure 2F The results of flow cytometry and apoptosis rate of RL cells treated with different concentrations of Siglitstat at 24h and 48h.
[0082] The above results show that sitagliptin induces apoptosis of FL cells and increases the apoptosis level of FL cells in a concentration-dependent manner.
[0083] Example 3 Siglistatin blocks the cell cycle of follicular lymphoma (FL) cell lines
[0084] Take 1×10 5 FL cell lines SC-1, Karpas 422, and RL were seeded in 24-well cell culture plates;
[0085] In the control group, cells were treated with DMSO at 5 μM, 10 μM, and 20 μM sitagliptin concentrations;
[0086] After 48 h of treatment, cells were collected by centrifugation at 300 g for 5 min, washed once with PBS, fixed with 75% alcohol at 4°C overnight, and analyzed by flow cytometry for cell cycle arrest after staining with PI for 15 min.
[0087] The results are as follows Figure 3A , Figure 3B , Figure 3C As shown in the figure, it can be seen that after the FL cell line was treated with sitagliptin, the number of G1 phase cells increased significantly and the number of G2 cells decreased significantly compared with the control group, indicating that sitagliptin can block the FL cell cycle process.
[0088] Example 4 Siglitstat inhibits cell clone formation of follicular lymphoma (FL) cell line
[0089] Take 1×10 4 FL cell lines SC-1, Karpas 422, and RL cells were seeded in 24-well cell culture plates;
[0090] In the control group, cells were treated with DMSO at 5 μM, 10 μM, and 20 μM sitagliptin concentrations;
[0091] After 72 hours of treatment, 1000 cells were counted in each well and plated. After clones were formed, the cells were stained with MTT (thiazolyl blue) and photographed.
[0092] The results are as follows Figure 4A , Figure 4B , Figure 4C , Figure 4D , Figure 4E and Figure 4FAs shown in the figure, it can be seen that after the FL cell line was treated with sitagliptin, the number of cloned cells was significantly reduced compared with the control group, indicating that sitagliptin can inhibit the clone formation of FL cells and is concentration-dependent.
[0093] Example 5 Effect of Siglistatin on PPAR Protein Levels
[0094] Take 5×10 5 FL cell lines SC-1, Karpas 422, and RL cells in the logarithmic growth phase were seeded in six-well cell culture dishes;
[0095] The cells were treated with DMSO in the control group, and the concentrations of sitagliptin sodium in the experimental group were set at 5 μM, 10 μM, and 20 μM;
[0096] After 24 h of treatment, cells were collected by centrifugation at 300 g for 5 min, lysed in lysate on ice for 1 h, and total protein was extracted for Western blot to detect the expression of PPARα, PPARγ, and PPARδ protein levels;
[0097] The results are as follows Figure 5A , Figure 5B and Figure 5C As shown in the figure, it can be seen that after SC-1, Karpas 422 and RL cells were treated with different concentrations of sitagliptin for 24 hours, the expression of PPARα was upregulated, while the expression of PPARγ and PPARδ was not significantly upregulated.
[0098] The results showed that sitagliptin mainly activated the protein expression of PPARα in SC-1, Karpas 422 and RL cells.
[0099] Example 6 Effect of Siglistatin on the Expression of FOXM1 and Its Downstream Target Genes in Follicular Lymphoma (FL) Cell Lines
[0100] Take 5×10 5 FL cell lines SC-1, Karpas 422, and RL cells in the logarithmic growth phase were seeded in six-well cell culture dishes;
[0101] The control group treated cells with DMSO at 5 μM, 10 μM, 20 μM, and 30 μM sitagliptin concentrations;
[0102] After 24 h of treatment, cells were collected by centrifugation at 300 g for 5 min, and half of the cells were lysed with 200 μL RIPA lysis buffer on ice for 1 h. Total protein was extracted for Western blot to detect the protein expression levels of FOXM1 and its downstream target genes;
[0103] The other half of the cells were added with 500 μL Trizol reagent, and total RNA was extracted using an RNA extraction kit. A reverse transcription kit was used to perform a reverse transcription experiment to obtain total cDNA. Finally, primers were designed for RT-PCR to detect the expression of FOXM1 and its downstream target genes at the mRNA level.
[0104] The results obtained with SC-1 cells are as follows Fig. 6A as well as Fig. 7A As shown in the figure, the Western blot results of protein expression levels after treatment with different concentrations of sitagliptin showed that the expression levels of FOXM1 and its downstream target genes C-MYC, CyclinD1, CyclinE1 and CyclinB1 were significantly decreased; at the same time, the reverse transcription experiment showed that the mRNA level expression of FOXM1 and its downstream target genes C-MYC, CyclinD1, CyclinE1 and CyclinB1 was significantly downregulated.
[0105] Similarly, the results obtained for Karpas 422 cells are as follows Figure 6B as well as Figure 7B As shown in the figure, the Western blot results of protein expression levels after treatment with different concentrations of sitagliptin showed that the expression levels of FOXM1 and its downstream target genes C-MYC, CyclinD1, CyclinE1 and CyclinB1 were significantly decreased; at the same time, the reverse transcription experiment showed that the mRNA level expression of FOXM1 and its downstream target genes C-MYC, CyclinD1, CyclinE1 and CyclinB1 was significantly downregulated.
[0106] Similarly, the results obtained for RL cells are as follows Figure 6C as well as Figure 7C As shown in the figure, the Western blot results of protein expression levels after treatment with different concentrations of sitagliptin showed that the expression levels of FOXM1 and its downstream target genes C-MYC, CyclinD1, CyclinE1 and CyclinB1 were significantly decreased; at the same time, the reverse transcription experiment showed that the mRNA level expression of FOXM1 and its downstream target genes C-MYC, CyclinD1, CyclinE1 and CyclinB1 was significantly downregulated.
[0107] Example 7 Siglitstat activates PPARα and inhibits the transcriptional activity of FOXM1
[0108] First, take 1×10 7 FL cell lines SC-1 and RL in the logarithmic growth phase were inoculated in 10-cm cell culture dishes;
[0109] The cells were treated with DMSO in the control group, and the concentration of sitagliptin sodium in the experimental group was set at 10 μM;
[0110] After 48 hours of treatment, cells were fixed with formaldehyde and collected by centrifug. 500 μL RIPA lysis buffer was added and the cells were ultrasonically disrupted. The cells were divided into two parts and antibodies against IGg and PPARα were added respectively to bind to the target protein-DNA complex after ultrasonication and incubated overnight.
[0111] The next day, Protein A / G beads were added to bind to the antibody-target protein-DNA complex, and the precipitate was washed and eluted. After cross-linking was resolved, DNA fragments were purified and enriched, and then analyzed by fluorescence quantitative qPCR.
[0112] The results are as follows Fig. 8A and Figure 8B As shown in the figure, it can be seen that sitagliptin can activate the expression of PPARα protein, and PPARα is enriched in the promoter region of the transcription factor FOXM1.
[0113] Secondly, take 2×10 5 293T cells in the logarithmic growth phase were seeded in a 24-well cell culture dish;
[0114] After the cells adhered to the wall, 3×flag-PPARα (0, 200ng, 400ng, 800ng), R-LUC and FOXM1-LUC plasmids were transfected, and the luciferase activity was detected after 24 hours.
[0115] The results are as follows Figure 8C As shown in the figure, it can be seen that PPARα can bind to the FOXM1 promoter region and inhibit the transcriptional expression of FOXM1.
[0116] The results showed that PPARα activated by sitagliptin can be enriched in the promoter region of FOXM1 and inhibit the gene transcription activity of FOXM1.
[0117] Example 8 Siglistatin inhibits the tumorigenicity of follicular lymphoma (FL) cell transplants
[0118] Collect 1×10 6 Logarithmically growing FL cell line SC-1 cells and RL cells were subcutaneously injected into CB17 mice to produce subcutaneous tumor transplants;
[0119] After the tumor is formed, the size of the transplanted tumor is measured with a vernier caliper. The drug is administered at a dose of 15 mg / kg / day for 10 days. The day of the start of drug administration is regarded as day 0. The animals are killed 10 days later for sampling, photographing and weighing, and the experimental results are statistically analyzed.
[0120] The results obtained with SC-1 cells are as follows Fig.9A , Fig. 9B and Fig. 9CAs shown in the figure, it can be seen that Siglitstat sodium can significantly inhibit the tumor formation process of subcutaneous transplanted tumors. Fig.9D , Fig.9E and Fig.9F As shown in the figure, it can be seen that sitagliptin can significantly inhibit the tumor formation process of subcutaneous transplanted tumors.
[0121] The applicant declares that the present invention uses the above-mentioned embodiments to illustrate the drug-loaded nanocomposite fiber membrane system and its preparation method and application, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
[0122] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
[0123] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. Application of PPAR agonists in the preparation of drugs for treating follicular lymphoma; The PPAR agonist is selected from any one of cigligliptin or its levorotatory isomer, crystalline form, amorphous form or pharmaceutically acceptable salt.
2. The use according to claim 1, It is characterized in that The pharmaceutically acceptable salt is any one of an alkali metal salt, an alkaline earth metal salt, an ammonium salt or a quaternary ammonium salt.
3. The use according to claim 2, It is characterized in that The pharmaceutically acceptable salt is an alkali metal salt.
4. The use according to claim 3, It is characterized in that The pharmaceutically acceptable salt is a sodium salt or a potassium salt.
5. The use according to claim 1, It is characterized in that The PPAR agonist downregulates the expression levels of transcription factor FOXM1 and its cell cycle-related genes.
6. The use according to claim 5, It is characterized in that The cell cycle-related genes include any one or a combination of at least two of CyclinB1, C-MYC, CyclinD1 or CyclinE1.
7. The use according to claim 1, It is characterized in that The medicine also contains pharmaceutically acceptable excipients.
8. The use according to claim 7, It is characterized in that The pharmaceutically acceptable excipients include any one of fillers, binders, wetting agents, disintegrants, solubilizers, osmotic pressure regulators, coating materials, colorants, pH regulators, antioxidants or antibacterial agents, or a combination of at least two of them.
Citation Information
Patent Citations
Application for chiglitazar and related compounds of chiglitazar
CN110934866A
Application of PPAR agonist in preparation of medicine for treating acute myeloid leukemia (AML)
CN113813387A
Modulators of mas-related g-protein receptor x4 and related products and methods
CN113939288A
Application of siolanib or pharmaceutically acceptable salt thereof in preparation of medicine for preventing or treating follicular lymphoma
CN115177620A
Combined pharmaceutical composition for preventing or treating follicular lymphoma and application thereof
CN116271057A
